Thursday, April 15 Highlights
Poster Session V
Multiple Sclerosis and Related Diseases: Drug Mechanisms
7:30 a.m.–12:00 p.m.
First author stand-by time 7:30 a.m.–9:00 a.m.
PD5.001 Effect of Immunomodulatory Agents (IMAs) on Cortical Inflammatory Lesions (CLs) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): A two-year Longitudinal Comparison Study, Paolo Gallo, Padova, Italy
PD5.002 Induction of Immune Tolerance in Multiple Sclerosis Patients by Epicutaneous Immunization with Myelin Peptides, Agata Walczak, Lodz, Poland
PD5.003 Glatiramer Acetate Immunomodulates Pro-inflammatory B Cell Function in Central Nervous System Autoimmune Disease, Deetje Hertzenberg, Munich, Germany
PD5.004 Laquinimod Induces Up-regulation of BDNF in Serum of Patients with Relapsing-Remitting Multiple Sclerosis, Jan Thöne, Bochum, Germany
PD5.005 Detection and Quantification of IFNB-1b-induced NAbs Using Various Assays and Laboratories, Hans Hartung, Dusseldorf, Germany
PD5.006 Prolonged Reduction in Circulating Lymphocytes after Discontinuation of FTY720 (fingolimod): Possible Relationship to Duration of Therapy, Mark Keezer, Montreal, Quebec, Canada
PD5.007 Interferon-beta Decreases Energetic Activity in CD4+-lymphocytes: A Possible Mechanism of Action, Aiden Haghikia, Bochum, Germany
PD5.008 Effect of Intramuscular Interferon Beta-1a on Gray Matter Atrophy in Relapsing-Remitting Multiple Sclerosis, Kunio Nakamura, Cleveland, OH
PD5.009 Vitamin D Metabolites Are Linked to Clinical and MRI Outcomes in Multiple Sclerosis Patients, Bianca Weinstock-Guttman, Buffalo, NY
PD5.010 Early Effects of Natalizumab on the Cognitive Functioning, Fatigue, and Quality of Life of African American Patients with Multiple Sclerosis, Judith Stephenson, Wilmington, DE
Frontiers in Clinical Neuroscience Plenary Session
9:00 a.m.–11:00 a.m.
MTCC, Exhibit Hall FG
Moderator: Stefan M. Pulst, MD, FAAN Chair, Science Committee and Scientific Program Subcommittee
This session focuses on translational research related to clinical issues of importance. Four physician-scientists outline their recent research findings, along with the clinical implications.
Exhibits
11:30 a.m.–4:00 p.m.
Complimentary Luncheon: 12:00 p.m.–2:00 p.m.
MTCC, Exhibit Hall DE
See the latest in pharmaceutical products, medical equipment, publications, and products to assist with practice management, teaching methods, and research activities.
Integrated Neuroscience:
Deep Brain Stimulation: Where Are We and Where Do We Go From Here?
12:00 p.m.–4:00 p.m.
Provides in-depth subspecialty concentration around a topic using a combination of presentations such as scientific sessions, case studies, short poster talks, discussions, invited speakers, and poster sessions.
Scientific Platform Sessions
1:30 p.m.–3:45 p.m.
Poster Session VI
Cerebrovascular Disease: Acute Stroke Therapy
3:00 p.m.–7:30 p.m.
First author stand-by time 6:00 p.m.–7:30 p.m.
PD6.001 The Impact of NIH Stroke Scale on Functional Outcome Varies by the Hemisphere of Involvement in Major Ischemic Stroke, Leonardo Batista, Boston, MA
PD6.002 Early Recurrence of Cerebral Ischemia in Patients with Symptomatic Carotid Artery Stenosis, Henning Mast, Zurich, Switzerland
PD6.003 Safety and Feasibility of Intravenous Autologous Bone Marrow Derived Stem Cell Therapy for Patients with Acute Ischemic Stroke: An Openlabel, Phase I Trial, Kameshwar Prasad, New Delhi, India
PD6.004 Utilization of Helicopter Transport for Patients with Suspected Acute Ischemic Stroke, Mark MacKenzie, Edmonton, AB, Canada
PD6.005 The Safety of Clopidogrel Loading in the Treatment of Acute Ischemic Stroke and Transient Ischemic Attacks, Lester Leung, New Orleans, LA
PD6.006 Are You Ever Too Old for Thrombolysis? Intravenous Recombinant Tissue Plasminogen Activator in Patients Age 80 and Older, Shirley Chen, San Francisco, CA
PD6.007 Use of Perfusion CT to Guide Stroke Thrombolysis Between 3 and 6 Hours Is Safe and Effective, Laszlo Sztriha, London, United Kingdom
PD6.008 Stroke Mimics Treated with IVTPA: A Retrospective Analysis, Mohamed Teleb, Phoenix, AZ
PD6.009 Thrombolysis for Acute Ischemic Stroke in Patients over 80 Years of Age: A Perspective from Clinical Practice, Laszlo Sztriha, London, United Kingdom
PD6.010 Borderline Elevation of International Normalized Ratio and Use of Intravenous Recombinant Tissue Plasminogen Activator, Harsh Aggarwal, Minneapolis, MN For more information, contact
NEW! AAN Awards Plenary Session
4:00 p.m.–6:00 p.m.
MTCC, Exhibit Hall FG
Moderator: Brenda Banwell, MD, Member, Science Committee
The Awards Plenary Session highlights some of the best and brightest in the field today, featuring presentations by the recipients of four top 2010 awards. Sure to become a staple of future Annual Meetings.
NEW! Highlights in the Field
Get essential updates covering the past year in your subspecialty or topic of interest. Sections will provide overviews in their areas, featuring scientific and educational abstracts, journal articles, subspecialty society updates, tips, resources, and more. See page 8 of the 2010 Annual Meeting Program for a list of participating sections and details.
Note: these sessions replace the Scientific Topic Highlights Programs.
